Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 17/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096642 | 1.00 | CXCR4 (0.53) | CXCR4HDAC1HDAC6KDM1ACHRM2 | |
| SCHEMBL4203768 | 1.00 | CXCR4 (0.53) | CXCR4HDAC1HDAC6KDM1ACHRM2 | |
| SCHEMBL4827397 | 0.91 | HDAC1 (0.54) | CXCR4HDAC1HDAC6 | |
| Bromide SCHEMBL6047391 | 0.89 | HDAC1 (0.53) | CXCR4HDAC1HDAC6 | |
| SCHEMBL30096620 | 0.88 | HDAC1 (0.55) | CXCR4HDAC1HDAC6ADRA2ACYP2D6 | |
| SCHEMBL14275061 | 0.87 | HDAC1 (0.51) | CXCR4HDAC1HDAC6ADRA2ACYP2D6 | |
| SCHEMBL21784360 | 0.87 | HDAC1 (0.51) | CXCR4HDAC1HDAC6ADRA2ACYP2D6 | |
| SCHEMBL3996453 | 0.86 | HDAC1 (0.56) | CXCR4HDAC1HDAC6ADRA2ACYP2D6 | |
| SCHEMBL29067448 | 0.85 | HDAC1 (0.52) | CXCR4HDAC1HDAC6CYP2D6DRD2 | |
| SCHEMBL30486101 | 0.85 | HDAC1 (0.52) | CXCR4HDAC1HDAC6CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672793-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672793-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220008410-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | X4 PHARMACEUTICALS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11045461-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200253953-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | X4 PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020047410-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | X4 PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-10548889-B1 | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150157630-A1 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USED RELATED THERETO | EMORY UNIVERSITY | 2015-06-11 | — | — | US | disclosed |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | ANORMED, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-8778967-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2012-11-29 | — | — | US | disclosed |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| EP-1628533-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008410-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885HDAC1 743/4885HDAC6 388/4885 |
| US-20080167341-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CXCR4 2/4885HDAC1 1094/4885HDAC6 1371/4885 |
| US-10548889-B1 | Compositions of CXCR4 inhibitors and methods of preparation and use | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885HDAC1 743/4885HDAC6 388/4885 |
| US-20200253953-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885HDAC1 743/4885HDAC6 388/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885HDAC1 1094/4885HDAC6 1371/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885HDAC1 1094/4885HDAC6 1371/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885HDAC1 1094/4885HDAC6 1371/4885 |
| US-20150038509-A1 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885HDAC1 1094/4885HDAC6 1371/4885 |
| US-20120301427-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CXCR4 2/4885HDAC1 1111/4885HDAC6 1365/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | CXCR4 2/4885HDAC1 1094/4885HDAC6 1371/4885 |
| US-11672793-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885HDAC1 743/4885HDAC6 388/4885 |
| US-20150157630-A1 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USED RELATED THERETO | CXCR4, CXCL12, CXCR2 | CXCR4 1/4885HDAC1 1143/4885HDAC6 1400/4885 |
| US-11045461-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885HDAC1 743/4885HDAC6 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.